10-QPeriod: Q1 FY2013

Cencora, Inc. Quarterly Report for Q1 Ended Dec 31, 2012

Filed February 8, 2013For Securities:COR

Summary

AmerisourceBergen Corporation (COR) reported solid revenue growth for the quarter ended December 31, 2012, driven by its Pharmaceutical Distribution segment and significant contributions from its 'Other' segment, bolstered by recent acquisitions. While overall revenue increased by 5.7% year-over-year to $21.5 billion, the company's gross profit saw a notable increase of 15.1%, partly due to a $12.3 million gain from antitrust litigation settlements. However, operating expenses also rose significantly by 27.2%, largely attributable to the integration costs of acquisitions, impacting the Pharmaceutical Distribution segment's operating income which saw a slight decrease. The company demonstrated a strong commitment to shareholder returns, increasing its quarterly cash dividend by 62% and actively repurchasing shares, spending $96.9 million to complete its previously announced $750 million share repurchase program and initiating a new $750 million program with $187.6 million spent in the quarter. Despite a substantial decrease in cash from operations compared to the prior year, primarily due to increased working capital needs associated with a new large customer contract, the company maintains adequate liquidity through its revolving credit facility and securitization facility.

Financial Statements
Beta

Key Highlights

  • 1Total revenue for the quarter grew 5.7% to $21.47 billion, driven by both the Pharmaceutical Distribution and 'Other' segments.
  • 2Gross profit increased by 15.1% to $671.9 million, aided by a $12.3 million gain from antitrust litigation settlements.
  • 3Operating expenses rose 27.2% to $384.7 million, primarily due to integration costs from recent acquisitions.
  • 4Net income from continuing operations was $162.2 million, or $0.69 per diluted share, a slight increase from the prior year.
  • 5The company significantly increased its quarterly cash dividend by 62% to $0.21 per share.
  • 6Shareholder returns were further supported by significant share repurchases totaling $96.9 million under a completed program and $187.6 million under a new program during the quarter.
  • 7Cash flow from operating activities decreased significantly to $(241.7) million, primarily due to increased accounts receivable and inventory related to a new large customer contract.

Frequently Asked Questions

Revenue growth was primarily driven by the Pharmaceutical Distribution segment, which saw a 4.7% increase, and a substantial 104.4% increase in the 'Other' segment, largely due to the contributions of recently acquired companies like World Courier and TheraCom. The new contract with Express Scripts, effective October 1, 2012, was also a key factor.

The new contract with Express Scripts, effective October 1, 2012, contributed to revenue growth but also led to a lower gross profit margin for ABDC, impacting overall profitability for the Pharmaceutical Distribution segment. It also significantly increased accounts receivable and merchandise inventories, leading to a negative impact on working capital and a decrease in cash flow from operations for the quarter.

AmerisourceBergen is committed to divesting its packaging and clinical trials services business, AndersonBrecon ('AB'). Its operations and results have been classified as discontinued operations for all periods presented in the financial statements.

The company is involved in ongoing legal matters. Notably, it finalized payments related to a $16 million civil settlement for a Qui Tam Matter concerning the distribution and sale of Amgen's Aranesp. Additionally, it is responding to subpoenas and legal complaints related to the diversion control of controlled substances. The company also recognized a $12.3 million gain from antitrust litigation settlements during the quarter.